Literature DB >> 18803289

Smoking and serum CA19-9 levels according to Lewis and secretor genotypes.

Sayo Kawai1, Koji Suzuki, Kazuko Nishio, Yoshiko Ishida, Rieko Okada, Yasuyuki Goto, Mariko Naito, Kenji Wakai, Yoshinori Ito, Nobuyuki Hamajima.   

Abstract

CA19-9, a marker for cancers of biliary tract, pancreas and colorectum, is not synthesized in those with no enzyme activity genotype (le/le) of Lewis (Le) gene. No enzyme activity genotype (se/se) of secretor (Se) gene is known to have an association with high serum CA19-9 levels. There are also variations in serum CA19-9 levels independent of the genotypes. This study aimed to examine the associations of serum CA19-9 levels with smoking, alcohol drinking and body mass index (BMI; kg/m(2)), after the adjustments of Le and Se genotypes. Subjects were 486 health check-up examinees (158 males and 328 females) aged from 39 to 90 years in Hokkaido, Japan. Genotyping was conducted for 3 polymorphisms; Le T59G (59T for Le allele and 59G for le allele), Se A385T (385A for Se allele and 385T for sej allele), and Se pseudogene (se5 allele). The genotypes of Le and Se were deterministic factors of serum CA19-9. Those with Le/Le & se/se had the highest mean, while CA19-9 was not detected or very low in those with le/le. Although no associations were observed with alcohol drinking and BMI, a significant association was observed with smoking. Among those with Le/Le, the geometric mean of CA19-9 was significantly lower for current smokers than for noncurrent smokers (p = 0.011 in 4-way ANOVA with age, sex and Se genotype). When hemoglobin A1c was further adjusted, the association became stronger (p = 0.0027). In addition to polymorphic variations, some components of cigarette smoke may influence the production or destruction of CA19-9. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18803289     DOI: 10.1002/ijc.23907

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  20 in total

1.  Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis.

Authors:  A Xue; C J Scarlett; L Chung; G Butturini; A Scarpa; R Gandy; S R Wilson; R C Baxter; R C Smith
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

2.  Surgical Indication for Advanced Intrahepatic Cholangiocarcinoma According to the Optimal Preoperative Carbohydrate Antigen 19-9 Cutoff Value.

Authors:  Yusuke Yamamoto; Teiichi Sugiura; Akiko Todaka; Yukiyasu Okamura; Takaaki Ito; Ryo Ashida; Yuko Kakuda; Yasuni Nakanuma; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2018-10       Impact factor: 3.352

3.  Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer.

Authors:  Toshiya Abe; Chiho Koi; Shiro Kohi; Ki-Byung Song; Koji Tamura; Anne Macgregor-Das; Naoki Kitaoka; Miguel Chuidian; Madeline Ford; Mohamad Dbouk; Michael Borges; Jin He; Richard Burkhart; Christopher L Wolfgang; Alison P Klein; James R Eshleman; Ralph H Hruban; Marcia Irene Canto; Michael Goggins
Journal:  Clin Gastroenterol Hepatol       Date:  2019-10-30       Impact factor: 11.382

4.  Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients.

Authors:  Christine C Hsu; Abhishek Goyal; Alina Iuga; Saravanan Krishnamoorthy; Valerie Lee; Elizabeth C Verna; Shuang Wang; Fei-Na Chen; Rosa Rodriguez; Jean Emond; Paul Berk; Jay Lefkowitch; Lorna Dove; Robert S Brown; Abby B Siegel
Journal:  Clin Transl Gastroenterol       Date:  2015-02-05       Impact factor: 4.488

5.  Preventive medical services not covered by public health insurance at Daiko Medical Center in Japan, 2004-2011.

Authors:  Takashi Tamura; Mio Kurata; Takaaki Kondo; Yasuyuki Goto; Yoshikazu Kamiya; Sayo Kawai; Yoko Mitsuda; Nobuyuki Hamajima
Journal:  Nagoya J Med Sci       Date:  2012-02       Impact factor: 1.131

6.  Factors associated with serum CA19-9 levels among healthy children: a cross-sectional study.

Authors:  Sayo Kawai; Nobuyuki Hamajima; Sueli M Oba-Shinjo; Lucy S Ito; Miyuki Uno; Suely K N Marie
Journal:  BMC Clin Pathol       Date:  2012-12-04

7.  Bead-Based Extracellular Vesicle Analysis Using Flow Cytometry.

Authors:  Katherine S Yang; Hsing-Ying Lin; Caleigh Curley; Marisa W Welch; Brian M Wolpin; Hakho Lee; Ralph Weissleder; Hyungsoon Im; Cesar M Castro
Journal:  Adv Biosyst       Date:  2020-10-25

Review 8.  The role of quantitative mass spectrometry in the discovery of pancreatic cancer biomarkers for translational science.

Authors:  Daniel Ansari; Linus Aronsson; Agata Sasor; Charlotte Welinder; Melinda Rezeli; György Marko-Varga; Roland Andersson
Journal:  J Transl Med       Date:  2014-04-05       Impact factor: 5.531

Review 9.  Can Molecular Biomarkers Change the Paradigm of Pancreatic Cancer Prognosis?

Authors:  Javier Martinez-Useros; Jesus Garcia-Foncillas
Journal:  Biomed Res Int       Date:  2016-09-01       Impact factor: 3.411

10.  Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 "STARD Compliant".

Authors:  J Martinez-Useros; T Georgiev-Hristov; A Borrero-Palacios; M J Fernandez-Aceñero; M Rodríguez-Remírez; L Del Puerto-Nevado; A Cebrian; M T Gomez Del Pulgar; A Cazorla; R Vega-Bravo; N Perez; A Celdran; J Garcia-Foncillas
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.